Naperville, IL -- (SBWIRE) -- 09/06/2013 -- Reportstack, provider of premium market research reports announces the addition of Multiple Sclerosis - Pipeline Review, H2 2013 market report to its offering
Multiple Sclerosis - Pipeline Review, H2 2013

Summary

, 'Multiple Sclerosis - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Multiple Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Multiple Sclerosis. Multiple Sclerosis - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Multiple Sclerosis.
- A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Multiple Sclerosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Alcon, Inc.
Baxter International Inc.
F. Hoffmann-La Roche Ltd.
Biogen Idec Inc.
Amgen Inc.
Eli Lilly and Company
Athersys, Inc.
GlaxoSmithKline plc
MedImmune LLC
Daiichi Sankyo Company, Ltd
Cytokine PharmaSciences, Inc.
Plexxikon Inc.
XenoPort, Inc.
Apitope International NV
Novartis AG
Isotechnika Pharma Inc.
Aphios Corporation
Acorda Therapeutics, Inc.
Actelion Ltd
Dong-A Pharmaceutical Co., Ltd.
Elan Corporation, plc
Kissei Pharmaceutical Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
Ono Pharmaceutical Co., Ltd.
Rigel Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited
Vertex Pharmaceuticals Incorporated
Zydus Cadila Healthcare Limited
Genmab A/S
Enzon Pharmaceuticals, Inc.
Hadasit Medical Research Services & Development Ltd
Paratek Pharmaceuticals, Inc.
Celgene Corporation
BrainStorm Cell Therapeutics Inc.
Merck KGaA
4SC AG
Addex Pharmaceuticals
EntreMed, Inc.
Evotec Aktiengesellschaft
Hemispherx Biopharma, Inc.
Hollis-Eden Pharmaceuticals, Inc.
Antisense Therapeutics Limited
Idera Pharmaceuticals, Inc.
Karo Bio
Almirall, S.A.
Lpath, Inc.
Bionomics Limited
PROLOR Biotech, Inc.
MultiCell Technologies, Inc.
Nutra Pharma Corporation
Opexa Therapeutics, Inc.
Compugen Ltd.
Critical Outcome Technologies Inc.
ACADIA Pharmaceuticals Inc.
Accentia Biopharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.
Zenotech Laboratories Limited
RegeneRx Biopharmaceuticals, Inc.
ProMetic Life Sciences Inc.
MorphoSys AG
Cytos Biotechnology AG
Pluristem Therapeutics Inc.
Resverlogix Corp.
Sareum Holdings plc
Santhera Pharmaceuticals Holding AG
Transgene Biotek Ltd
Stem Cell Therapeutics Corp.
Morphotek, Inc.
Digna Biotech, S.L.
Antitope Ltd.
Axxam SpA
Bayhill Therapeutics, Inc.
Probiodrug AG
Phenex Pharmaceuticals AG
Hutchison MediPharma Limited
CREABILIS Therapeutics S.r.l.
Trophos SA
Ache Laboratorios Farmaceuticos S/A
Artielle ImmunoTherapeutics, Inc.
Argos Therapeutics, Inc.
Affectis Pharmaceuticals AG
ProtAffin Biotechnologie AG
Allozyne, Inc.
Coronado Biosciences, Inc.
Q Therapeutics, Inc.
Catabasis Pharmaceuticals, Inc.
Five Prime Therapeutics, Inc.
Vaccinex, Inc.
Innate Therapeutics Limited
Kineta, Inc.
MSM Protein Technologies, Inc.
Vascular Biogenics Ltd.
Xention Limited
Txcell SA
Phage Biotechnology Corporation
Theraclone Sciences, Inc.
TcL Pharma SAS
Biotica Technology Ltd
Siena Biotech S.p.A.
Omeros Corporation
Bolder Biotechnology, Inc.
Aegis Therapeutics, LLC
Xencor, Inc.
Adeona Pharmaceuticals, Inc.
Trillium Therapeutics Inc.
Cellceutix Corporation
Biovista Inc.
SanBio, Inc.
Provid Pharmaceuticals, Inc.
Epiphany Biosciences, Inc.
Biokine Therapeutics Ltd.
KYORIN Pharmaceutical Co., Ltd.
OncoImmune, Inc.
to-BBB technologies BV
Daval International Ltd.
Hy BioPharma Inc.
Medistem, Inc.
PharmaEssentia Corporation
KAHR medical Ltd.
M's Science Corporation
Pharnext SAS
Ascenion GmbH
Amplimmune, Inc.
Lycera Corp.
Neuraltus Pharmaceuticals, Inc.
RhinoCyte, Inc.
Vakzine Projekt Management GmbH
Biopartners Holdings AG
Pfenex Inc.
Cellmid Ltd
Varinel, Inc.
Cognosci, Inc.
Immune Technologies and Medicine

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/140877/multiple-sclerosis-pipeline-review-h2-2013.html